ISRCTN99828560已完成不适用
A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision for the treatment of patients with magentic resonance imaging defined high risk rectal cancer
Royal Marsden NHS Foundation Trust (UK)0 个研究点目标入组 164 人开始时间: 2006年10月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 164
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged 18 years or over
- •2. Histological diagnosis of adeno- or undifferentiated non-small cell carcinoma of rectum
- •3. High risk operable rectal cancer as defined by the presence on MRI of at least one of the following:
- •a. tumours within 1 mm of mesorectal fascia i.e. circumferential resection margin threatened or involved
- •b. T3 tumours at/below levators
- •c. tumours extending into more than or equal to 5 mm into peri-rectal fat
- •d. T4 tumours (including the involvement of bladder or vagina if surgical resection is possible with clear margins)
- •e. presence of extra-mural venous invasion (primary tumour is therefore at least T3)
- •4. World Health Organisation (WHO) performance status of zero to two
- •5. No evidence of metastatic disease as determined by Computerised Tomography (CT) scan of chest and abdomen or other investigations such as Positron Emission Tomography (PET) scan or biopsy if required
- •6. Adequate bone marrow function with platelets more than 100 x 10^9/l, White Blood Cells (WBC) more than 3 x 10^9/l and neutrophils more than 1.5 x 10^9/l
- •7. Serum bilirubin less than 1.5 x Upper Limit of institutional Normal range (ULN) and transaminases less than 2.5 x ULN
- •8. Serum creatinine less than ULN or calculated creatinine clearance more than 50 ml/min
- •9. No concurrent uncontrolled medical condition
- •10. No active malignant disease other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix in the last ten years
- •11. Life expectancy of more than three months
- •12. Adequate contraceptive precautions if relevant
- •13. Informed written consent
排除标准
- •1. Any contraindications to MRI (e.g. patients with pacemakers)
- •2. Medical or psychiatric conditions that compromise the patient?s ability to give informed consent
- •3. Patients with rectal cancer which is deemed inoperable at diagnosis should not be entered into the study even if they are potentially operable if their primary is successfully downstaged by neoadjuvant treatment. This includes patients with locally advanced inoperable disease, such as tumour extending beyond the mesorectal fascia into pelvic side wall structures, or situations where surgical resection with clear margins is unlikely to be possible
- •4. T1-2 rectal cancer at any level
- •5. Presence of metastatic disease or recurrent rectal tumour
- •6. Concurrent uncontrolled medical conditions
- •7. Any previous chemotherapy or radiotherapy, and any investigational treatment for rectal cancer
- •8. Pregnancy or breast feeding
- •9. Patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract
- •10. Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac dysrhythmia, e.g. atrial fibrillation, even if controlled with medication) or myocardial infarction within the last 12 months
- •11. Patients with any symptoms or history of peripheral neuropathy
研究者
相似试验
进行中（未招募）
1 期
A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision for the treatment of patients with magnetic resonance imaging (MRI) defined high risk rectal cancer. - EXPERT-CHigh risk operable rectal adenocarcinomaMedDRA version: 13.1 Level: PT Classification code 10038038 Term: Rectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-004707-38-GBRoyal Marsden NHS Trust164
进行中（未招募）
不适用
A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision for the treatment of patients with magnetic resonance imaging (MRI) defined poor risk rectal cancer. - EXPERT-CPoor risk operable rectal adenocarcinomaEUCTR2004-004707-38-SEProf David Cunningham164
进行中（未招募）
1 期
A trial testing a new agent for patients with diffuse large B cell lymphoma (DLBCL) who have heart conditions and unable to receive standard treatmentDiffuse large B cell lymphomaMedDRA version: 21.0 Level: PT Classification code 10012818 Term: Diffuse large B-cell lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001900-39-GBniversity College London132
进行中（未招募）
不适用
A multicentre randomised Phase II clinical trial to demonstrate equivalent pharmacodynamic efficacy and tolerability of two updosing schedules for ALK-Flex SQEUCTR2008-006921-14-DEALK-Abelló Arzneimittel GmbH
已完成
不适用
A multicentre phase II randomised controlled trial of a parent/carer-targeted intervention to improve quality of life in families of young cancer survivors.Quality of lifeDistressPsychological adjustmentMental Health - AnxietyMental Health - DepressionCancer - Any cancerACTRN12613000270718niversity of New South Wales76